News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
康希諾生物(06185.HK)PCV24啟動臨床試驗 完成首例受試者入組
康希諾生物(06185.HK)公布，其開發的24價肺炎球菌多糖結合疫苗(CRM197/破傷風類毒素)(PCV24)近日正式啟動I/II期臨床試驗，並完成首例受試者入組。(jl/da)~阿思達克財經新聞網址: www.aastocks.com
Reset
Send
The window will close in 5 seconds
康希諾生物(06185.HK)PCV24啟動臨床試驗 完成首例受試者入組
Close
Recommend
5
Positive
3
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

康希諾生物(06185.HK)  -1.060 (-4.237%)    Short selling $1.45M; Ratio 4.646%   公布，其開發的24價肺炎球菌多糖結合疫苗(CRM197/破傷風類毒素)(PCV24)近日正式啟動I/II期臨床試驗，並完成首例受試者入組。(jl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-04 16:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.